Company Description
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation.
It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer’s disease.
The company was incorporated in 2019 and is based in San Diego, California.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 25, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Zhen Li |
Contact Details
Address: 5871 Oberlin Drive, Suite 200 San Diego, California 92121 United States | |
| Phone | (877) 232-7974 |
| Website | adarx.com |
Stock Details
| Ticker Symbol | ADRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1802369 |
| CUSIP Number | 00654F105 |
| ISIN Number | US00654F1057 |
| Employer ID | 84-4145188 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zhen Li, Ph.D. | President, Chief Executive Officer and Director |
| Ryan Fisk, M.B.A. | Chief Financial Officer and Chief Business Officer |
| A. Robert MacLeod, Ph.D. | Chief Scientific Officer |
| Rui Zhu, Ph.D. | Chief Technology Officer |
| Robert Ackles | Chief People Officer |
| Erez Chimovits, M.B.A. | Interim Chairman |
| Ting Feng, Ph.D. | Director |
| Simeon George, M.D., M.B.A. | Director |
| Carl L. Gordon, Ph.D., CFA | Director |
| Ying Huang, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 5, 2026 | SCHEDULE 13D | Filing |
| Oct 2, 2026 | SCHEDULE 13D | Filing |
| Oct 1, 2026 | SCHEDULE 13G | Filing |
| Sep 28, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 28, 2026 | 424B4 | Prospectus |
| Sep 24, 2026 | EFFECT | Notice of Effectiveness |
| Sep 24, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Sep 24, 2026 | CERT | Certification by an exchange approving securities for listing |
| Sep 22, 2026 | 8-A12B | Registration of securities |